The burden of rare diseases

American Journal of Medical Genetics, Part A

Volumn 179, Issue 6, 2019, Pages 885-892

  Ferreira, Carlos R ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

burden of disease; orphan drugs; prevalence; rare disease

Indexed keywords

ORPHAN DRUG;

ACCESS TO INFORMATION; DISEASE ASSOCIATION; DISEASE BURDEN; DRUG APPROVAL; EUROPE; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; HEALTH CARE UTILIZATION; HUMAN; ICD-10; INTERNET; JAPAN; MEDICAL LITERATURE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SYSTEMATIC REVIEW; UNITED STATES; DRUG MANUFACTURE; HEALTH CARE DELIVERY; HEALTH SURVEY; META ANALYSIS;

DELIVERY OF HEALTH CARE; HUMANS; MORBIDITY; MORTALITY; ORPHAN DRUG PRODUCTION; POPULATION SURVEILLANCE; PREVALENCE; RARE DISEASES;

EID: 85065143360     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.61124     Document Type: Review

References (55)

1. Angelis, A., Tordrup, D., & Kanavos, P. (2015). Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy (Amsterdam, Netherlands), 119(7), 964–979. https://doi.org/10.1016/j.healthpol.2014.12.016
2. Asbury, C. H. (1991). The Orphan Drug Act. The first 7 years. JAMA, 265(7), 893–897.
3. Baird, P. A., Anderson, T. W., Newcombe, H. B., & Lowry, R. B. (1988). Genetic disorders in children and young adults: A population study. American Journal of Human Genetics, 42(5), 677–693.
4. Bell, S. A., & Tudur Smith, C. (2014). A comparison of interventional clinical trials in rare versus non-rare diseases: An analysis of ClinicalTrials.Gov. Orphanet Journal of Rare Diseases, 9(170), 170. https://doi.org/10.1186/s13023-014-0170-0
5. Bernal, J. E., Ortega, G., & Umana, A. (1983). The contribution of genetic disease to paediatric mortality in a university hospital in Bogota. Journal of Biosocial Science, 15(4), 465–471.
6. Carter, C. O. (1956). Changing patterns in the causes of death at the Hospital for Sick Children. Great Ormond Street Journal, (11), 65–68.
7. Chiu, A. T. G., Chung, C. C. Y., Wong, W. H. S., Lee, S. L., & Chung, B. H. Y. (2018). Healthcare burden of rare diseases in Hong Kong—Adopting ORPHAcodes in ICD-10 based healthcare administrative datasets. Orphanet Journal of Rare Diseases, 13(1), 147. https://doi.org/10.1186/s13023-018-0892-5
8. Chong, J. X., Buckingham, K. J., Jhangiani, S. N., Boehm, C., Sobreira, N., Smith, J. D., … Bamshad, M. J. (2015). The genetic basis of Mendelian phenotypes: Discoveries, challenges, and opportunities. American Journal of Human Genetics, 97(2), 199–215. https://doi.org/10.1016/j.ajhg.2015.06.009
9. Chung, C. S., & Myrianthopoulos, N. C. (1987). Congenital anomalies: Mortality and morbidity, burden and classification. American Journal of Medical Genetics, 27(3), 505–523. https://doi.org/10.1002/ajmg.1320270304
10. Coi, A., Santoro, M., Pierini, A., Marrucci, S., Pieroni, F., & Bianchi, F. (2017). Prevalence estimates of rare congenital anomalies by integrating two population-based registries in Tuscany, Italy. Public Health Genomics, 20(4), 229–234.
11. Copeland, G. E., & Kirby, R. S. (2007). Using birth defects registry data to evaluate infant and childhood mortality associated with birth defects: An alternative to traditional mortality assessment using underlying cause of death statistics. Birth Defects Research. Part A, Clinical and Molecular Teratology, 79(11), 792–797. https://doi.org/10.1002/bdra.20391
12. Costa, T., Scriver, C. R., & Childs, B. (1985). The effect of Mendelian disease on human health: A measurement. American Journal of Medical Genetics, 21(2), 231–242.
13. Cunniff, C., Carmack, J. L., Kirby, R. S., & Fiser, D. H. (1995). Contribution of heritable disorders to mortality in the pediatric intensive care unit. Pediatrics, 95(5), 678–681.
14. Czeizel, A., & Sankaranarayanan, K. (1984). The load of genetic and partially genetic disorders in man. I. Congenital anomalies: Estimates of detriment in terms of years of life lost and years of impaired life. Mutation Research, 128(1), 73–103.
15. Day, N., & Holmes, L. B. (1973). The incidence of genetic disease in a university hospital population. American Journal of Human Genetics, 25(3), 237–246.
16. Detiček, A., Locatelli, I., & Kos, M. (2018). Patient access to medicines for rare diseases in European countries. Value in Health, 21(5), 553–560.
17. Divino, V., DeKoven, M., Kleinrock, M., Wade, R. L., & Kaura, S. (2016). Orphan drug expenditures in the United States: A historical and prospective analysis, 2007–18. Health Affairs (Project Hope), 35(9), 1588–1594.
18. EURORDIS. (2005). European Conference on Rare Diseases 2005 Report (p. 93). Retrieved from https://www.eurordis.org/IMG/pdf/EN-ECRDtotal-2.pdf
19. EURORDIS. (2017). Access to treatment: Unequal care for European rare disease patients. Rare Barometer. Retrieved from http://download2.eurordis.org.s3.amazonaws.com/Access%20to%20treatment/access%20to%20treatment%20EN.pdf
20. Evaluate. (2018). EvaluatePharma's Orphan Drug Report 2018. Retrieved from http://info.evaluategroup.com/rs/607-YGS-364/images/OD18.pdf
21. FitzPatrick, D. R., Skeoch, C. H., & Tolmie, J. L. (1991). Genetic aspects of admissions to a paediatric intensive care unit. Archives of Disease in Childhood, 66(5), 639–641.
22. Gammie, T., Lu, C. Y., & Babar, Z. U.-D. (2015). Access to orphan drugs: A comprehensive review of legislations, regulations and policies in 35 countries. PLoS One, 10(10), e0140002.
23. Guillem, P., Cans, C., Robert-Gnansia, E., Aymé, S., & Jouk, P. S. (2008). Rare diseases in disabled children: An epidemiological survey. Archives of Disease in Childhood, 93(2), 115–118.
24. Hall, J. G., Powers, E. K., Mcllvaine, R. T., & Ean, V. H. (1978). The frequency and financial burden of genetic disease in a pediatric hospital. American Journal of Medical Genetics, 1(4), 417–436.
25. Hartley, T., Balcı, T. B., Rojas, S. K., Eaton, A., Canada, C. R., Dyment, D. A., & Boycott, K. M. (2018). The unsolved rare genetic disease atlas? An analysis of the unexplained phenotypic descriptions in OMIM®. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 178(4), 458–463. https://doi.org/10.1002/ajmg.c.31662
26. Herder, M. (2017). What is the purpose of the Orphan Drug Act? PLoS Medicine, 14(1), e1002191.
27. Heron, M. (2018). Deaths: Leading causes for 2016 (National Vital Statistics Report No. Volume 67, Number 6) (p. 77).
28. Hsu, J. C., Wu, H.-C., Feng, W.-C., Chou, C.-H., Lai, E. C.-C., & Lu, C. Y. (2018). Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan's National Health Insurance Research Database. PLoS One, 13(9), e0204206. https://doi.org/10.1371/journal.pone.0204206
29. Hudome, S. M., Kirby, R. S., Senner, J. W., & Cunniff, C. (1994). Contribution of genetic disorders to neonatal mortality in a regional intensive care setting. American Journal of Perinatology, 11(2), 100–103.
30. Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development (2010). In M. J. Field & T. F. Boat (Eds.), Profile of rare diseases. Washington, DC: National Academies Press Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK56184/
31. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. (2009). The Food and Drug Administration's orphan drug program. Washington, DC: National Academies Press Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK50974/
32. Jacob, J., Kamitsuka, M., Clark, R. H., Kelleher, A. S., & Spitzer, A. R. (2015). Etiologies of NICU deaths. Pediatrics, 135(1), e59–e65.
33. Jimenez-Sanchez, G., Childs, B., & Valle, D. (2014). The effect of Mendelian disease on human health. In A. L. Beaudet, B. Vogelstein, K. W. Kinzler, S. E. Antonarakis, A. Ballabio, K. M. Gibson, & G. Mitchell (Eds.), The online metabolic and molecular bases of inherited disease (Vol. 1—Book, Section). New York, NY: The McGraw-Hill Companies Retrieved from http://www.ommbid.mhmedical.com/content.aspx?aid=1102918817
34. Kumar, P., Radhakrishnan, J., Chowdhary, M. A., & Giampietro, P. F. (2001). Prevalence and patterns of presentation of genetic disorders in a pediatric emergency department. Mayo Clinic Proceedings, 76(8), 777–783.
35. Ling, E. W., Sosuan, L. C., & Hall, J. C. (1991). Congenital anomalies: An increasingly important cause of mortality and workload in a neonatal intensive care unit. American Journal of Perinatology, 8(3), 164–169.
36. Logviss, K., Krievins, D., & Purvina, S. (2018). Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study. PLoS One, 13(4), e0194494. https://doi.org/10.1371/journal.pone.0194494
37. Luzzatto, L., Hyry, H. I., Schieppati, A., Costa, E., Simoens, S., Schaefer, F., … Second Workshop on Orphan Drugs participants. (2018). Outrageous prices of orphan drugs: A call for collaboration. Lancet (London, England), 392(10149), 791–794.
38. Malam, F., Hartley, T., Gillespie, M. K., Armour, C. M., Bariciak, E., Graham, G. E., … Dyment, D. A. (2017). Benchmarking outcomes in the neonatal intensive care unit: Cytogenetic and molecular diagnostic rates in a retrospective cohort. American Journal of Medical Genetics. Part A, 173(7), 1839–1847. https://doi.org/doi:10.1002/ajmg.a.38250
39. Mazzucato, M., Visonà Dalla Pozza, L., Manea, S., Minichiello, C., & Facchin, P. (2014). A population-based registry as a source of health indicators for rare diseases: The ten-year experience of the Veneto Region's rare diseases registry. Orphanet Journal of Rare Diseases, 9(1), 37. https://doi.org/10.1186/1750-1,172-9-37
40. McCandless, S. E., Brunger, J. W., & Cassidy, S. B. (2004). The burden of genetic disease on inpatient care in a children's hospital. American Journal of Human Genetics, 74(1), 121–127.
41. Moya, A., Hernández, M., & Mellado, C. (2016). Prevalence of genetic diseases in admissions to a tertiary care hospital pediatric service. Revista Medica De Chile, 144(2), 188–193. https://doi.org/10.4067/S0034-98872016000200007
42. O'Malley, M., & Hutcheon, R. G. (2007). Genetic disorders and congenital malformations in pediatric long-term care. Journal of the American Medical Directors Association, 8(5), 332–334.
43. Orphanet. (2018). Prevalence and incidence of rare diseases: Bibilographic data. Diseases listed by decreasing prevalence, incidence or number of published cases (Orphanet Report Series No. Number 2). Retrieved from http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_decreasing_prevalence_or_cases.pdf
44. Richter, T., Nestler-Parr, S., Babela, R., Khan, Z. M., Tesoro, T., Molsen, E., … International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. (2015). Rare disease terminology and definitions-a systematic global review: Report of the ISPOR rare disease special interest group. Value in Health, 18(6), 906–914.
45. Roberts, D. F., Chavez, J., & Court, S. D. (1970). The genetic component in child mortality. Archives of Disease in Childhood, 45(239), 33–38.
46. Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012). NIH Image to ImageJ: 25 years of image analysis. Nature Methods, 9(7), 671–675.
47. Schulpen, T. W. J., van Wieringen, J. C. M., van Brummen, P. J., van Riel, J. M., Beemer, F. A., Westers, P., & Huber, J. (2006). Infant mortality, ethnicity, and genetically determined disorders in The Netherlands. European Journal of Public Health, 16(3), 291–294.
48. Scriver, C. R., Neal, J. L., Saginur, R., & Clow, A. (1973). The frequency of genetic disease and congenital malformation among patients in a pediatric hospital. Canadian Medical Association Journal, 108(9), 1111–1115.
49. Shire. (2014). Rare disease impact report: Insights from patients and the medical community. The Journal of Rare Disorders, 1–34.
50. Soneda, A., Teruya, H., Furuya, N., Yoshihashi, H., Enomoto, K., Ishikawa, A., … Kurosawa, K. (2012). Proportion of malformations and genetic disorders among cases encountered at a high-care unit in a children's hospital. European Journal of Pediatrics, 171(2), 301–305.
51. Stevenson, D. A., & Carey, J. C. (2004). Contribution of malformations and genetic disorders to mortality in a children's hospital. American Journal of Medical Genetics. Part A, 126A(4), 393–397.
52. The Lancet Neurology. (2011). Rare neurological diseases: A united approach is needed. The Lancet Neurology, 10(2), 109.
53. Walker, C. E., Mahede, T., Davis, G., Miller, L. J., Girschik, J., Brameld, K., … Weeramanthri, T. S. (2016). The collective impact of rare diseases in Western Australia: An estimate using a population-based cohort. Genetics in Medicine, 19, 546.
54. Wojcik, M. H., Schwartz, T. S., Yamin, I., Edward, H. L., Genetti, C. A., Towne, M. C., & Agrawal, P. B. (2018). Genetic disorders and mortality in infancy and early childhood: delayed diagnoses and missed opportunities. Genetics in Medicine, 20, 1396–1404.
55. Yoon, P. W., Olney, R. S., Khoury, M. J., Sappenfield, W. M., Chavez, G. F., & Taylor, D. (1997). Contribution of birth defects and genetic diseases to pediatric hospitalizations. A population-based study. Archives of Pediatrics & Adolescent Medicine, 151(11), 1096–1103.